(Nasdaq: CVKD): The Under-$50M Market Cap Stock Targeting a Billion-Dollar Cardiovascular Problem

Cadrenal Therapeutics (NASDAQ: CVKD) Is Redefining Cardiovascular Safety With The Only Drug Designed Specifically For Patients With LVAD, ESKD + AFib, And MHV.

Show Me the Stockarrow
logo
logo
logo

From Refugee to Nasdaq: Meet the Leader Behind CVKD

Quang X. Pham’s Journey Fuels Cadrenal’s Mission to Serve the Most Overlooked Patients in Cardiology

Meet the Founder

Quang X. Pham didn’t take the conventional route to Wall Street. He fled Vietnam as a war refugee, became the first Vietnamese American aviator in the U.S. Marine Corps, broke records in biotech sales, and took Cadrenal Therapeutics public on Nasdaq.

Now, with Underdog Nation (published by Forbes Books), Pham shares the ER Approach™ — Effort + Results — that powers his leadership and Cadrenal’s bold mission to transform cardiovascular safety for neglected patient groups.

“Success isn’t reserved for the privileged — it belongs to those who fight for it.”

Quang X. Pham, CEO, Cadrenal Therapeutics (CVKD)

Why Investors Are Watching

Investors are closely watching CVKD for several reasons

logo
logo
logo

Guidance from advisors

Guidance from renowned scientific advisors affiliated with Duke, Harvard, and the Cleveland Clinic

Key information about CVKD

logo

Ticker

NASDAQ: CVKD

logo

Lead Asset

Tecarfarin (oral VKA)

logo

Primary Indication

LVAD Anticoagulation

logo

FDA Status

Fast Track and Orphan Drug (2x)

logo

Market Size

More than $2 billion combined peak potential across three indications

logo

Clinical Stage

Late-stage, Phase 3-ready

logo

Strategic Partner

Abbott, contributing to trial design, site access, and awareness

Why Tecarfarin is Different

logo

Fewer Drug Interactions

Better metabolism by bypassing the CYP450 pathway, resulting in fewer drug interactions

logo

Renal-Friendly Solution

Safer use in patients with renal failure

logo

Tailored for Rare Needs

It is the only late-stage anticoagulant in development for LVADs and rare cardiovascular indications

Patients With Implanted Cardiac Devices Are Left Behind by Big Pharma

Challenges faced by patients include:

(01)

DOACs Don’t Work

LVAD patients are not covered by DOACs, and warfarin is ineffective

(02)

Kidney Patients Left Out

Over 70% of kidney failure patients with AFib receive no anticoagulation due to safety concerns

(03)

No Options for MHV

There are no approved therapies beyond warfarin for mechanical heart valves

(04)

Bleeding Still Unsolved

Current therapies result in uncontrolled bleeding, stroke, and death — and the issue remains unaddressed

Unlocking Untapped Markets in Cardiovascular Safety

Each of these heart-related conditions could be worth over $500 million in market potential. Tecarfarin is showing strong results compared to older drugs like warfarin, with data showing it keeps patients in the safe range more consistently.

logo

LVAD

Granted Orphan Drug designation and trial-ready

logo

MHV

Application currently pending

logo

ESKD + AFib

Granted Orphan Drug and Fast Track status

Don’t Miss a Beat

Be the first to receive updates on CVKD’s clinical milestones, media coverage, and investor news. Alerts are sent directly to your inbox or phone.

Phone

You may receive recurring email or SMS alerts from Stockverse. Message and data rates may apply. You can unsubscribe at any time.

Investor Questions

Cadrenal Therapeutics is developing a novel anticoagulant designed to reduce the risks associated with current blood thinners, such as bleeding and stroke, especially in high-risk patient populations where treatment options remain limited.
Tecarfarin is designed to offer more predictable effects and fewer interactions with certain medications and foods. Its unique metabolism may support more consistent results in patients who respond variably to conventional anticoagulants.
Abbott is involved by providing the anticoagulation monitoring technology used in the clinical trials of Tecarfarin, helping ensure accurate and consistent dosing.
The unmet need remains significant because millions of patients are unable to use existing anticoagulants effectively—often due to bleeding risks, drug interactions, or unpredictable response—leaving them without consistent or suitable treatment options.
logo

Cadrenal Therapeutics has been featured on prominent platforms including NASDAQ, BusinessWire, Yahoo Finance, and Seeking Alpha.

“With Abbott’s Backing And A $2B Addressable Market, CVKD Could Become The Go-To Anticoagulant For Thousands Of Ignored Patients.”

logo
Stockverse Logo
Stockverse LogoStockverse LogoStockverse LogoStockverse Logo

© 2025 Stockverse Kit. All rights reserved.

MASTER LEGAL DISCLAIMER

Effective Date: August 2024

Last Updated: May 17, 2025

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

IMPORTANT SUMMARY — PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Genesis One Holdings LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

Relqo Media LLC has been retained by Genesis One Holdings LLC to provide promotional media services for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). As of the effective date:

  • Relqo Media LLC is receiving cash compensation for digital investor awareness campaigns.
  • The total compensation paid for these services is $25,000 per week, paid weekly, for the period beginning January 1, 2025 through July 1, 2025, totaling $650,000.
  • Genesis One Holdings LLC may own, acquire, or dispose of shares in CVKD during or after the campaign period.

This relationship creates a material conflict of interest. Relqo Media’s content regarding CVKD should be considered promotional, biased, and financially motivated.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with CVKD should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:

  • CVKD’s stock may increase temporarily during this promotion,
  • Trading volume may rise sharply, and
  • The price may fall after the campaign ends or selling begins.

These patterns are typical of stock promotions, and you should proceed accordingly.

6. NO RELIANCE – INVESTOR RESPONSIBILITY

The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:

  • Read public filings from the SEC,
  • Consult a licensed financial adviser,
  • Understand risks such as dilution, insider selling, and volatility, and
  • Recognize that speculative stocks often lack financial transparency.

We accept no responsibility for losses incurred due to actions taken based on our Communications.

7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR

Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

  • Subjective,
  • Not independently verified,
  • Created to highlight potential upside and omit downsides,
  • Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

  • Email and newsletter distributions,
  • SMS/MMS text campaigns,
  • Social media posts and influencers,
  • Google and native display ads,
  • Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

  • Compensation arrangements,
  • Conflicts of interest,
  • Risks,
  • Limitations of our role, and
  • The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

  • Investment losses,
  • Inaccuracies,
  • Technical delays,
  • User misunderstandings,
  • Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE – ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

  • Exit our websites,
  • Unsubscribe from our communications,
  • Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

  • You will not rely on any statements made by Relqo Media for investment purposes,
  • You waive any claim that our content was a material factor in your investment decision,
  • You have read, understood, and accepted this disclaimer in full.

© 2024 Relqo Media LLC. All Rights Reserved.

Legal Contact: 📧 support@stockverse.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.